Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 10/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955122 | 1.00 | AURKA (0.40) | AURKARPS6KB1EGFRPDE11ACXCR1 | |
| SCHEMBL30097291 | 0.90 | EGFR (0.42) | AURKARPS6KB1EGFRPDE11ACXCR1 | |
| SCHEMBL27409145 | 0.90 | EGFR (0.42) | AURKARPS6KB1EGFRPDE11ACXCR1 | |
| SCHEMBL27409170 | 0.89 | PDE11A (0.40) | AURKARPS6KB1EGFRPDE11ACXCR1 | |
| SCHEMBL27409178 | 0.86 | EGFR (0.37) | AURKARPS6KB1EGFRCXCR1CXCR2 | |
| SCHEMBL27409171 | 0.86 | PDPK1 (0.47) | AURKARPS6KB1EGFRCXCR1CXCR2 | |
| SCHEMBL30972173 | 0.84 | ENPP1 (0.46) | AURKARPS6KB1EGFRPDE11APDE4A | |
| SCHEMBL27244262 | 0.84 | ENPP1 (0.46) | AURKARPS6KB1EGFRPDE11APDE4A | |
| SCHEMBL30097221 | 0.81 | AURKA (0.41) | AURKARPS6KB1 | |
| SCHEMBL30097173 | 0.81 | AURKA (0.40) | AURKARPS6KB1EGFRCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, ENTPD5 | AURKA 3480/4885RPS6KB1 1181/4885EGFR 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.